Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Lohse I, Azzam DJ, Al-Ali H, Volmar C-, Brothers SP, Ince TA, et al. Ovarian Cancer Treatment Stratification Using Drug Sensitivity Testing. Anticancer Res. 2019;39(8):4023-4030.

Zhang Y, Mun SR, Linares JF, Towers CG, Thorburn A, Diaz-Meco MT, et al. Mechanistic insight into the regulation of SQSTM1/p62. Autophagy. 2019;15(4):735-737.

Falzone ME, Rheinberger J, Lee B-, Peyear T, Sasset L, Raczkowski AM, et al. Structural basis of Ca-dependent activation and lipid transport by a TMEM16 scramblase. Elife. 2019;8.

Marshall CH, Imada EL, Tang Z, Marchionni L, Antonarakis ES. CDK12 inactivation across solid tumors: an actionable genetic subtype. Oncoscience. 2019;6(5-6):312-316.

Davuluri M, Long B, Semple S, Villanueva-Siles E, Aboumohamed A. Primary Urethral Melanoma: A Case Report and Literature Review. Urology. 2019;126:1-4.

Guerrero-Preston R, Lawson F, Rodriguez-Torres S, Noordhuis MG, Pirini F, Manuel L, et al. Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. Cancer Prev Res (Phila). 2019;12(4):255-270.

Ali R, Yang Y, Antkowiak M, Gabr A, Mora R, Abouchaleh N, et al. Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. Cardiovasc Intervent Radiol. 2019;42(5):700-711.

Isharwal S, Hu W, Sarungbam J, Chen Y-, Gopalan A, Fine SW, et al. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. J Pathol. 2019;248(3):260-265.

Magleby R, Bemis DA, Kim D, Carroll KC, Castanheira M, Kania SA, et al. First reported human isolation of Staphylococcus delphini. Diagn Microbiol Infect Dis. 2019;94(3):274-276.

Musselman K, Glynn S, Mosquera JM, Elemento O, Sboner A, Beltran H, et al. Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. Gynecol Oncol Rep. 2019;28:54-57.